III期结肠癌含奥沙利铂辅助治疗时长:ASCO临床实践指南
ASCO专家小组基于六项IDEA协作随机对照试验的汇总数据制定指南,针对完全切除的III期结肠癌患者,比较含奥沙利铂和氟嘧啶辅助化疗3个月与6个月的时长。推荐高复发风险(T4和/或N2)患者接受6个月辅助化疗;低复发风险(T1、T2或T3且N1)患者可选6个月或3个月,因3个月方案不良事件可能减少且无病生存无显著差异。专家小组推荐共享决策。
要点
- 高复发风险(T4和/或N2)的III期结肠癌患者应接受6个月含奥沙利铂辅助化疗。
- 低复发风险(T1、T2或T3且N1)患者可选6个月或3个月方案,3个月方案不良事件可能减少且无病生存无显著差异。
- 专家小组推荐共享决策,考虑患者特征、价值观偏好及治疗时长相关的获益与风险。
核心结论
- 对于完全切除的III期结肠癌患者,辅助化疗时长应根据复发风险分层:高风险者推荐6个月,低风险者可选择6个月或3个月。
- 专家小组推荐采用共享决策方法确定治疗时长。
研究设计与样本
- ASCO召集专家小组,对相关研究进行系统评价,指南推荐基于专家小组对证据的审查。
- 证据基础为六项IDEA协作随机对照试验的汇总数据。
主要发现
- 推荐适用于正在接受含奥沙利铂和氟嘧啶辅助化疗的完全切除的III期结肠癌患者。
- 推荐基于近期比较6个月与3个月含奥沙利铂化疗的临床试验汇总分析结果。
关键数值与推荐
- 高复发风险(T4和/或N2)患者应接受6个月辅助化疗。
- 低复发风险(T1、T2或T3且N1)患者可选6个月辅助化疗或较短3个月疗程,基于3个月方案不良事件可能减少且无病生存无显著差异。
- 专家小组推荐共享决策,考虑患者特征、价值观和偏好及其他因素,并讨论治疗时长相关的潜在获益与风险。
临床怎么用
- 根据复发风险分层(高风险T4和/或N2,低风险T1、T2或T3且N1)确定辅助化疗时长。
- 与患者进行共享决策,讨论6个月与3个月方案的获益和风险。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To develop recommendations for duration of adjuvant chemotherapy with a fluoropyrimidine and oxaliplatin for patients with completely resected stage III colon cancer based on the results of trials of 3 months compared with 6 months of treatment. METHODS: ASCO convened an Expert Panel and conducted a systematic review of relevant studies. The guideline recommendations were based on the review of evidence by the Expert Panel. RESULTS: Pooled data from the six International Duration Evaluation of Adjuvant Chemotherapy (IDEA) Collaboration randomized controlled trials comprise the evidence base for these guideline recommendations. RECOMMENDATIONS: The recommendations for therapy duration apply to patients with completely resected stage III colon cancer who are being offered adjuvant chemotherapy with oxaliplatin and a fluoropyrimidine. Recommendations are informed by the findings of a recent pooled analysis of clinical trials that compared 6 months versus 3 months of oxaliplatin-based chemotherapy. For patients at a high risk of recurrence (T4 and/or N2), adjuvant chemotherapy should be offered for a duration of 6 months. For patients at a low risk of recurrence (T1, T2, or T3 and N1), either 6 months of adjuvant chemotherapy or a shorter duration of 3 months may be offered on the basis of a potential reduction in adverse events and no significant difference in disease-free survival with the 3-month regimen. In determining duration of therapy, the Expert Panel recommends a shared decision-making approach, taking into account patient characteristics, values and preferences, and other factors and including a discussion of the potential for benefit and risks of harm associated with treatment duration. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .
引用
- Lieu C, Kennedy EB, Bergsland E, et al. Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline. J Clin Oncol. 2019. PMID: 30986117. doi:10.1200/JCO.19.00281
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。